Brio Pharma, a Japanese-based subsidiary of Ohsong Pharm Co. (CEO Kim Young-joong), which specializes in medical product brokerage between Korea and Japan, opened its office in downtown Tokyo on March 6. The picture above shows the opening of the office. The opening ceremony was attended by employees of the Ohsong Pharm and related companies, Japanese employees Brio Pharma, KOTRA and officials from the Tokyo administration.

Brio Pharma, founded in July 2017 with a 100 % investment by Ohsong Pharm, has moved its office to Otemachi, central Tokyo. Currently, Tokyo is expected to complete its " pharmaceutical manufacturing and selling " license in March, the first of its kind in Korea. Although the licensing requirements are difficult, having the manufacturing and selling license of a drug provides the basis for handling a wide range of functions, such as application for a license, clinical and nonclinical testing, and wholesale medicine. Brio Pharma works with experienced Japanese local experts and Korean staff to provide market research, patent analysis and product selection for pharmaceutical bio companies hoping to enter Japan. It has a liaison office in Seoul to communicate quickly with its Korean partners.

" Considering the conservative Japanese pharmaceutical industry culture, experience and know-how accumulated in Japan are essential. We will do our best to help Korean pharmaceutical companies enter the tricky Japanese market.